Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
|
|
- Logan Smith
- 6 years ago
- Views:
Transcription
1 Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International
2 Agenda Overview of key areas of Directive 2001/20/EC Applications to EC and CA Safety Reporting Investigational Medicinal Product Current implementation in France Current implementation in EU Member States
3 Overview of Key Areas Scope Implementation of good clinical practice for all clinical trials in Europe including bioavailability and bioequivalence studies Do not apply to non-interventional studies Timelines Adopted 4 th April 2001 / Published in OJ 1 st May 2001 Member States to implement Directive into national law until 1 st May st May 2004 Provision to be applied
4 Directive 2001/20/EC Overview of Key Areas 25 Member States of European Union 15 old Member States Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden, United Kingdom 10 new Countries which joined the EU on 1 st May 2004: Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovak Republic, Slovenia Norway, Iceland and Liechtenstein Since 01 January 2000 for Registration Procedures Total: 25 EU Countries + Iceland, Norway and Liechtenstein
5 Overview of Key Areas Pharmacogivilance (SAE Reporting) General Provisions Scope Manufacture and Import of IMP S Labelling Verification of GCP & GMP Commencement of a Clinical Trial Conduct of a Clinical Trial (Amendments) Exchange of Information Clinical Trials Directive Ethics Committee Single Opinion Definitions Protection of Clinical Trial Subjects Clinical Trials on incapacitated adults not able to give informed consent Clinical Trials on Minors Suspension/ End of a Trial
6 Directive 2001/20/EC Application to Ethic Committee Ethics Committee : One country - One vote Opinion within 60 days Single request issued within the examination period Drugs for gene therapy, somatic cellular therapy & products with GMOs: The 60 days period can be extended for 30 days The 90 days may be extended for another 90 days (180 days) in case expert committee is consulted Drugs for xenogenic cellular therapy: Authorisation period not limited EC review: Sequentially or in parallel with CA review (choice of the applicant) Applicant: sponsor, legal representative, PI
7 Application to Competent Authorities Commencement of a Clinical Trial If no objection: Start within 60 days of valid application. MS may shorten evaluation time Drugs for gene therapy, somatic cellular therapy and products with GMOs: + 30 days Written authorisation may be required: biotech medicinal products, biological products of human or animal origin, products containing biological components or manufactured with biological components Written authorisation mandatory: medicinal products for gene therapy, somatic & xenogenic cellular therapy and products with GMOs
8 Application to Competent Authorities Commencement of a Clinical Trial Sponsor or Legal Representative in Community to submit request for authorisation Copy of EC opinions if available Check language of submission with CA EudraCT number A contact person per Member State
9 Application to Competent Authorities Investigational Medicinal Product Dossier (IMPD) IMPD to be presented in CTD format Full IMPD Quality data + critical analysis of data + assessment of safety of product Summaries of all previous studies Overall risk and benefit assessment (Critical analysis of risk/benefit) Simplified IMPD IMP assessed previously as part of MA in any MS or as CTA to the CA concerned Discussion on potential risks/benefits of proposed trial to include For marketed product when within conditions of SPC approved Comparative trials
10 Application to Competent Authorities Data for Application to CA Data to be submitted to CA are not fully harmonised throughout all countries Table in Guideline with the different requirements per country
11 Application to EC and CA Conduct of a Clinical Trial Amendments To be submitted to competent authority of MS and EC EC: 35 days for opinion If favourable opinion of EC and no objections of CA the study may proceed according to amendment
12 Application to EC and CA Suspension, End of a Clinical Trial Trial stopped prematurely: EC & CA to be informed within 15 days Specific form to be completed Completion as planned: CA & EC to be informed within 90 days Summary of trial report to be submitted within one year of end of the trial to EC & CA (format to comply with ICH E3)
13 SUSARS Report to Directive 2001/20/EC Safety Reporting Competent Authorities and Ethic Committees concerned Member States may take measures to permit that the ECs concerned may only receive expedited individual reports of SUSAR occurred in subjects recruited in that MS, provided All SUSARs from MSs and where applicable, 3rd countries are reported at least quarterly (a line listing accompanied by a brief report highlighting the main points for concern; copy to CA) Any changes increasing the risk to subjects and any new issues that may affect adversely the safety of the subjects or the conduct of the trial should be provided asap, but not later that 15 days.
14 SUSARS Report to Investigator Sites Safety Reporting If appropriate: information aggregated in a line listing of SUSARs in periods warranted by the nature of the clinical development project and the volume of SUSARs generated Concise summary of the evolving safety profile added to the line listing If significant safety issue identified (receipt of an individual case report or review of aggregate data) sponsor to issue asap a communication to all investigators
15 Safety Reporting Format of SUSAR Reports Electronic reporting (expedited reporting to CA) Format & content Eudravigilance Guidance CIOMS-I: accepted standard SUSARs should be identified by A unique clinical trial identification (Eudract number, or in case of non-eu trials the sponsor s trial protocol code) A unique case identification: case identification number in the sponsor s safety database
16 Directive 2001/20/EC Eudravigilance database Safety Reporting Established & maintained by EMEA SUSARs entered into CT module of Eudravigilance database Required for : Overview of SUSAR occurrence in all clinical trials in Community Facilitation of communication between CAs, Commission & EMEA Separate review of SUSARs occurring in a single MS Generation of signals concerning safety of IMPs Through it's interface with Eudract database, review of safety data in particular populations groups of products therapeutic areas/ pathology/ indication trials conducted by a given sponsor
17 Annual Safety Reports Safety Reporting Once a year throughout clinical trial or upon request by a CA Several clinical trials conducted with the same IMP: Report to include a Global Analysis of the safety profile based on ALL clinical trials The reporting period starts with the date of the first authorisation for one of these trials by the CA in any Member State and ends after the close of the last trial in any MS
18 Investigational Medicinal Product Manufacturing Manufacturing of IMP to be GMP compliant (manufactured in accordance with Directive 2003/94/EC) Labelling of Investigational Medicinal Product Annex13 of Directive 2003/94/EC Manufacturers, Importer subject to an authorisation (application!) GMP inspections Audit of manufacturing sites and testing site by MS
19 Investigational Medicinal Product Qualified Person At least one QP for GMP compliance and batch release Each batch manufactured and checked according to EU-GMP In case of import, QP at manufacturing site and at importer site For comparator: either documentation on GMP or complete re-testing
20 Current Implementation in France Directive not in force yet Pilot Phase for start of phase 1 studies since Nov Pilot Phase for phase 1, 2, 3, 4 studies since 01 May 2004 Start of trial now 3 options 1. Under current Law, i.e. Loi Huriet 2. Acccording to Pilot Phase 3. Under Law Huriet and Pharmacovigilance according to Directive 2001/20/EC After implementation of Directive: transition period for studies running under Law Huriet after which all trials have to comply with Directive
21 Current Implementation in France Start dates for AFSSAPS evaluation are fixed Start on Monday (15 Nov, 22 Nov, etc.) Dossier to be submitted Friday prior Monday Paper submission before 12 a.m. Electronic submission 8 a.m. Evaluation time phase 1 study phase 2, 3 study simplified dossier, phase 4 14 days. If questions: 30 days 30 days. If questions: 60 days 14 days During pilot phase, opinion of AFSSAPS not mandatory to start study ( demande d évaluation )
22 Current Implementation in France Biological products, biologicals used in production: viral safety report to AFSSAPS before CCPPRB Products for gene therapy, somatic & xenogenic cellular therapy and products with GMOs: Viral Safety and AFSSAPS approval Already under Law Huriet - only new format
23 Current Implementation in France AFSSAPS to be informed on study start (first IC signed in France) Amendment to be submitted at fixed dates unless urgency Study report within 1 year of study end (Annex 1 of ICH note on Clinical study reports) Electronic reporting preferred
24 Current Implementation in France Major impacts in France Procedure Authorisation of studies & amendments vs notification SUSARs reporting to EC Declaration of study end and final report Logistic Preparation of dossiers Eudract database / Pharmacovigilance CT Module database and electronic submissions GCP and GMP for all clinical studies
25 Current Implementation in the EU Not fully implemented in all EU Member States Current situation National transposition: no consistent process, no timing Amendments for ongoing studies: no harmonised approach Ethic Committees procedure and single opinion: different procedures in Member States
26 Benefits First step to more harmonisation in area of clinical trials in EU better harmonisation of application formats for EC and CA Quality IMP: Draft CHMP/EMEA Guideline planned for Nov. 04 Shorter time frame for early development in phase I studies Heads of Agencies have set up a Clinical Trials Coordination Group Possibility for a mutual recognition of CT applications in future? For MA faster approval procedure with less problems because CA knows the product already?
27 Thank you! Omnicare Clinical Research understands what it takes to develop and market new drugs. phase of development
28 List of implementing texts Detailed guideline on the principles of GCP in the conduct in the EU of clinical trials on medicinal product for human use Detailed guidance on the application format and documentation to be submitted in an application for an ethics committee opinion on a clinical trial on a medicinal product for human use Detailed guidance on the submission to competent authorities of a request for authorisation of a clinical trial on a medicinal product for human use Detailed guidance on the European clinical trials database (EUDRACT) Detailed guidance on the database of Suspected Unexpected Serious Adverse Reactions Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use Detailed guidelines on the trial master file and archiving Detailed guidelines on the qualifications of inspectors who should verify compliance in clinical trials with the provisions of good clinical practice for an investigational medicinal product Detailed guidelines on inspection procedures for the verification of GCP compliance Detailed guidelines on inspection procedures for the verification of GMP compliance Detailed guidelines on the Community basic format and the contents of the application for a manufacturing and/or import authorisation of an investigational medicinal product for human use Commission Directive on the requirements to obtain an authorisation to manufacture or import an investigational medicinal product and the requirements to be met by the holder of this authorisation Revised Annex 13 Manufacture of investigational medicinal products, Volume 4 of the rules governing medicinal products in the European Union Commission Directive 2003/94/EEC as amended
29 Glossary ADR Adverse Drug Reaction CA Competent Authority EC Ethics Committee EU European Union EMEA European Medicines Agency GCP Good Clinical Practice GMO Genetically Modified Organism GMP Good Manufacturing Practice IMPD Investigational medicinal product dossier MAA Marketing Authorization Application MS Member State SAE Serious Adverse Event SUSAR Suspected unexpected serious adverse reaction
Impact of Clinical EU Directive on the implementation of Early development studies in Europe
Impact of Clinical EU Directive on the implementation of Early development studies in Europe Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Syposium Strasbourg
More informationOVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20
OVERVIEW OF DIRECTIVE 2001/20 Paul Derbyshire Background & History CONDUCT OF TRIALS III/3976/88 (July 1991) ICH/135/95 (January 1997) 2001/20 75/318 Q,S,E Testing Part 4B: GCP 91/507 MEDICINAL PRODUCTS
More informationMultinational Clinical Trials in EU How NCAs can improve the system? Dr C. Bélorgey, Head of Clinical Trials Department Afssaps Chair of CTFG
Multinational Clinical Trials in EU How NCAs can improve the system? Dr C. Bélorgey, Head of Clinical Trials Department Afssaps Chair of CTFG Bonn 30 April 2010 European CTs bodies (Competent Authorities)
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems, medical products and innovation Medicines: policy, authorisation and monitoring PHARM 723 PHARMACEUTICAL COMMITTEE 18 October
More informationEU Perspective on Regulatory Issues for Biologics
Oncology Biologics Development Primer 29 February 2008 Robert Charnas Disclosure Employee and shareholder of Amgen, Inc. Thousand Oaks, CA Worked in Basel, Switzerland for 19 Years and dealt with European
More informationSession 13: Prequalification Within the Context of Global Fund Procurements
Session 13: Prequalification Within the Context of Global Fund Procurements Established in 2002 Global Fund Attracts and disburses additional resources to prevent and treat AIDS, tuberculosis (TB), and
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-11 29 MAY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS 3 1
More informationANNEX. CHAPTER I General principles
ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I
More informationCTFG 10 September 2010
CTFG 10 September 2010 Clinical Trial Facilitation Group CTFG comments on the European Commission public consultation document CT3: draft detailed guidance on the collection, verification and presentation
More informationENVIRONMENTAL RISK ASSESSMENTS: EU CLINICAL TRIALS WITH GMO-BASED ATMPS ANN GORMAN, AMGEN LTD, UK 16 DECEMBER 2016
ENVIRONMENTAL RISK ASSESSMENTS: EU CLINICAL TRIALS WITH GMO-BASED ATMPS ANN GORMAN, AMGEN LTD, UK 16 DECEMBER 2016 SIMPLIFIED DEFINITIONS Genetically Modified Organism (GMO)? An organism, e.g virus, plant,
More informationTrack III: International Clinical Trials: Global Compliance Norms and EU Focus
Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health
More informationCAP CONTEXT INDICATORS
CAP CONTEXT INDICATORS 2014-2020 24. AGRICULTURAL TRAINING OF FARM MANAGERS 2017 update CONTEXT INDICATOR 24: AGRICULTURAL TRAINING OF FARM MANAGERS Learning by doing is still the main form of for the
More informationEU Clinical Trial Regulation A view from the Industry
Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications Deleted: 06 AUGUST 2014 AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationRegulatory Affairs: Study Report of New Drug Registration Process in European Union
95 Review Article Regulatory Affairs: Study Report of New Drug Registration Process in European Union Yogeshkumar B. Viradiya*, Manoj B. Dagwar, Swapnil T. Lanjewar Department of Regulatory Affairs, Institute
More informationGuidance for applicants for ethics committee opinion on the conduct of a clinical trial of pharmaceuticals
KLH-EC-01 APPLICATION FOR ETHICS COMMITTEE OPINION ON THE CONDUCT OF A CLINICAL TRIAL IN THE CZECH REPUBLIC requirements governing the documentation to be submitted This guideline is being published in
More informationRelating to the transnational hiring-out of workers in the framework of the provision of services
FORM FOR USE (OPTIONAL) BY THE REQUESTING ADMINISTRATION I. REQUEST FOR INFORMATION Relating to the transnational hiring-out of workers in the framework of the provision of services Pursuant to Article
More informationHighlights of the proposed Clinical Trials Regulation in Europe
Highlights of the proposed Clinical Trials Regulation in Europe Dr Daryl Rees 22 January 2013 Proposed Clinical Trials Regulation On 17July 2012, the Commission adopted the proposal for a "Clinical Trials
More informationRevising the Pharmaceutical Landscape in the EU
Revising the Pharmaceutical Landscape in the EU The Industry Perspective Dr. Christine-Lise Julou June 2008 1 Revising the pharmaceutical landscape in Europe Preamble New Legislation Other regulatory initiatives
More informationESF Ex-Post evaluation
ESF 2007-2013 Ex-Post evaluation Fields marked with * are mandatory. Open public consultation Questionnaire Please consult the background document as it provides useful information on the European Social
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-1011 16 SEPTEMBER 2017 29 MAY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS
More informationCouncil of the European Union Brussels, 10 November 2016 (OR. en)
Conseil UE Council of the European Union Brussels, 10 November 2016 (OR. en) Interinstitutional File: 2016/0186 (COD) 13660/16 LIMITE NOTE CULT 101 AELE 77 EEE 41 CODEC 1506 From: Permanent Representatives
More informationPharmacovigilance and product data
Future Legislation: pharmacovigilance EMA Veterinary Medicines Info Day 16-17 March 2017, London Presented by Jos Olaerts on 17 March 2017 European Medicines Agency - Veterinary Medicines Division An agency
More informationICH GCP Revision and EU Clinical Trial Regulation
ICH GCP Revision and EU Clinical Trial Regulation Sinead Curran, GCP/PhV Inspection Manager Irish Research Nurses Network Annual National Conference Friday, 17 November 2017 Overview Guideline for Good
More informationPerformance of Rural Development Programmes of the period - Your Voice
Performance of Rural Development Programmes of the 2007-2013 period - Your Voice Fields marked with * are mandatory. Introduction The Commission will use the information gathered through this survey together
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 22 October 2012
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA PHARM 608 PHARMACEUTICAL COMMITTEE 22 October 2012 Subject: Hospital exemption
More informationClinical trial applications in the EU and US
Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation
More informationRSC/CT Det. no. 1/2013
RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please
More informationInformation on the Member States requirement for the nomination of a pharmacovigilane (PhV) contact person at national level
19 July 2017 EMA/INS/PhV/445316/2017 Committees and Inspections Information on the Member s requirement for the nomination of a pharmacovigilane (PhV) contact person at national level Based on Pharmacovigilance
More information1. Introduction. The core part of the EASA management system framework focuses on the following elements:
EASA survey to RMT.0251 Phase II SMS for EASA Part-21 design organisations, EASA Part-21 production organisations and EASA Part-145 maintenance organisations Fields marked with * are mandatory. 1. Introduction
More informationAustria: Experiences with the Zonal evaluation procedure Applying Regulation (EC) No.1107/2009
Austria: Experiences with the Zonal evaluation procedure Applying Regulation (EC) No.1107/2009 Vienna, Ceureg Meeting, 15-16 October 2012 Rebecca Reboul Institute for Plant Protection Products AGES, Austrian
More informationRegulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for
Medicinal Products for Human Use - CZECH REPUBLIC Competent authority Contact Details Contact Name 1 State Institute for Control of Drugs- SÚKL (Státní ústav pro kontrolu léčiv) Phone +420 272 185 111
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationFelicia Favorito Clinical Operations Leader TESARO Inc.
Felicia Favorito Clinical Operations Leader TESARO Inc. Navigating your way around protocols which intervene with country specific regulations to ensure valuable time isn t lost during the clinical trial
More informationComments on: Name of Organisation
Comments on: THE RULES GOVERNING MEDICINAL PRODUCTS IN THE EUROPEAN UNION VOLUME 10 - GUIDANCE DOCUMENTS APPLYING TO CLINICAL TRIALS HARMONISED REQUIREMENTS FOR NON INVESTIGATIONAL MEDICINAL PRODUCTS IN
More informationAvailability of human medicinal products in Europe how big is the problem and what can we do?
Availability of human medicinal products in Europe how big is the problem and what can we do? Kristin Raudsepp Director General Estonian State Agency of Medicines The presentation Initiative by the regulators
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationImplementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G.
Implementation of the EU-law Tom Van Paepegem Quality co-ordinator D.R.U.G. History (1) World War II: Experiments by Nazi-doctors 1946: Nüremberg process 1947: Nüremberg codeddd History (2) 10 basic ethical
More informationClinical Trials Environment EU Legislation: Ausblick auf die neue Gesetzgebung für klinische Prüfungen
The Future of the Regulatory Berlin, 31.05.2013 Clinical Trials Environment EU Legislation: Qualifizierungstag für Study Nurses Ausblick auf die neue Gesetzgebung für klinische Prüfungen Dr. med. Ingrid
More informationChapter 28 Pharmaceutical acquis (human and veterinary medicinal products)
Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products) Screening meeting with Serbia 5 December 2014 DG SANTE D5: Medicinal products - authorisations, EMA; D6: Medicinal products -
More informationCOMMENTS FROM EUROPABIO GENERAL COMMENTS
SUBMISSION OF COMMENTS ON DETAILED GUIDANCE FOR THE REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES, NOTIFICATION OF SUBSTANTIAL AMENDMENTS
More informationEU Construction & Demolition Waste Management Protocol Dublin, 22 June 2017
EU Construction & Demolition Waste Management Protocol Dublin, 22 June 2017 EUROPEAN COMMISSION - DG GROWTH - Unit C.1 Clean technologies & products - Vincent Basuyau - vincent.basuyau@ec.europa.eu Resource
More informationResearch Ethics Committees and Ethical Review in Europe
Multidisciplinary Workshop on Research Ethics Committees and Ethical Review in Europe 19 th January 2010, Barcelona, Spain On behalf of the Road Map Initiative for Clinical Research in Europe FINAL REPORT
More informationFolder Name Documents included Explanation
Structure for the documents to be submitted in the case of electronic submission of applications for clinical trials at the BfArM (Federal Institute for Drugs and Medical Devices) / Paul-Ehrlich Institut
More informationThis document is a preview generated by EVS
TECHNICAL REPORT RAPPORT TECHNIQUE TECHNISCHER BERICHT CEN/TR 15628 July 2007 ICS 03.100.30 English Version Maintenance - Qualification of Maintenance personnel Maintenance - Qualification du personnel
More informationOverview of Privacy Requirements and Compliance Issues in International Clinical Trials
Overview of Privacy Requirements and Compliance Issues in International Clinical Trials Health Care Compliance Association Research Compliance Conference October 18-20, 2009 Minneapolis, MN 1 Today s Presenters
More informationOfficial Journal of the European Union L 153/9
14.6.2007 Official Journal of the European Union L 153/9 COMMISSION REGULATION (EC) No 653/2007 of 13 June 2007 on the use of a common European format for safety certificates and application documents
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationPublic Consultation on the European Solidarity Corps
Contribution ID: 94df7e58-a466-43b9-a2cd-6e6b82df0c88 Date: 30/03/2017 14:21:49 Public Consultation on the European Solidarity Corps Fields marked with * are mandatory. Introduction The European Solidarity
More informationStakeholder consultation on the mid-term review of the 2011 White Paper on transport
1 von 11 01.06.2015 14:57 Case Id: 25d75e1b-6c50-4ec3-a704-189176957ecf Stakeholder consultation on the mid-term review of the 2011 White Paper on transport Fields marked with are mandatory. Please provide
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 29.06.2005 COM(2005) 286 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE COMMITTEE OF THE REGIONS AND THE EUROPEAN ECONOMIC
More informationPublic consultation on enhanced cooperation between Public Employment Services (PES)
Public consultation on enhanced cooperation between Public Employment Services (PES) Fields marked with * are mandatory. Introduction The European Network of Public Employment Services (PES Network) was
More informationDetailed Data from the 2010 OECD Survey on Public Procurement
ANNEX G Detailed Data from the 2010 OECD Survey on Public Procurement This annex provides data for each responding country on the transparency of the public procurement cycle, as well as the online availability
More informationBelgian Center for Pharamcovigilance for medicines for Human use (BCPH): faggafmps.be
Medicinal Products for Human Use - BELGIUM Competent authority Contact Details Contact Name 1 Federal Agency for Medicines and Health Products (FAMHP) / Agence Fédérale des Médicaments et des Produits
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public health and Risk assessment Pharmaceuticals Brussels, 01 June 2010 SANCO/C/8/SF/dn D(2010) 326199 THE RULES GOVERNING MEDICINAL PRODUCTS
More informationto ensure that the public is properly informed about the state of the environment.
Contribution ID: 3d857566-b12a-41a3-b91d-7d9a03167ba4 Date: 20/10/2017 16:24:00 Public consultation to support the evaluation of the European Environment Agency (EEA) and its European Environment Information
More informationdistributors with FMD & DR
Challenges for wholesale distributors with FMD & DR implementation on national level Monika Derecque-Pois Director General, GIRP (European Healthcare Distribution Association) 9 November 2017 Who needs
More information(c) The terms of the agreement are set out in the Annex to this Note Verbale.
Note Verbale No EDD/2018/001 Her Britannic Majesty's Foreign and Commonwealth Office presents its compliments to the Secretariat of the United Nations Framework Convention on Climate Change and has the
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 6.10.2005 COM(2005)473 final COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL on the appropriateness of establishing rules on
More informationENERGY PRIORITIES FOR EUROPE
ENERGY PRIORITIES FOR EUROPE Presentation of J.M. Barroso, President of the European Commission, to the European Council of 4 February 2011 Contents 1 I. Why energy policy matters II. Why we need to act
More informationFRAMEWORK CONVENTION ON CLIMATE CHANGE - Secretariat CONVENTION - CADRE SUR LES CHANGEMENTS CLIMATIQUES - Secrétariat KEY GHG DATA
UNITED NATIONS NATIONS UNIES FRAMEWORK CONVENTION ON CLIMATE CHANGE - Secretariat CONVENTION - CADRE SUR LES CHANGEMENTS CLIMATIQUES - Secrétariat KEY GHG DATA Greenhouse Gas Emissions Data for 1990 2003
More informationANNEXES. to the COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL
EUROPEAN COMMISSION Brussels, 23.7.2014 COM(2014) 520 final ANNEXES 1 to 3 ANNEXES to the COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL Energy Efficiency and its contribution
More informationEnvironmental Best Practices, It Begins with Us: Business, Local Governments and International Community Should Work Together
Environmental Best Practices, It Begins with Us: Business, Local Governments and International Community Should Work Together Jung Wan Lee, PhD Boston University, United States Objectives of the Paper
More informationPROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group
European Medicines Agency Inspections London, 20 April 2009 EMEA/INS/PhV/85058/2008 Procedure no: INS/PhV-V/2 PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP Ad Hoc PhV Inspectors
More informationRisk-adapted approach to clinical trial regulation and monitoring
European Leukemia Net Workshop Mannheim, February 1st, 2011 Risk-adapted approach to clinical trial regulation and monitoring Jacques Demotes jacques.demotes@inserm.fr www.ecrin.org Risk-based approach
More informationEmissions Trading System (ETS): The UK needs to deliver its share of the total EU ETS emissions reduction of 21% by 2020, compared to 2005;
Emissions Trading System (ETS): The UK needs to deliver its share of the total EU ETS emissions reduction of 21% by 2020, compared to 2005; Non-ETS emissions: The Effort Sharing Decision sets a target
More informationRegulatory Newsletter January - March 2014
Regulatory Newsletter January - March 2014 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree Deliver motto!
More informationEven implementation of the EU Timber Regulation Harmonizing and improving the implementation of the EUTR in the EUTR countries
Even implementation of the EU Timber Regulation Harmonizing and improving the implementation of the EUTR in the EUTR countries Thünen Institute, 09 October 2018, Hamburg EUTR EU MS obligations for application
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, [ ] ENTR/F/2/SF D(2009) [ ] Detailed guidance for the request for authorisation of a clinical trial
More informationFederal agency for medicines and health products
Federal agency for medicines and health products The implementation of the EU CT Regulation : Overview of the different projects in progress Greet Musch KCE Symposium, 12 th October 2016 1: Overview of
More informationFEDERAL PUBLIC SERVICE DOMESTIC AFFAIRS EUROPEAN CITIZENS VOTE FOR THE EUROPEAN PARLIAMENT. ON THE 13th JUNE 2004 (+ LOGO INTERIEUR)
VERSION : 18 NOVEMBRE 2003 (page 1) DRAFT FOLDER 2004 EU CITIZENS - ENGLISH ------ FEDERAL PUBLIC SERVICE DOMESTIC AFFAIRS EUROPEAN CITIZENS VOTE FOR THE EUROPEAN PARLIAMENT ON THE 13th JUNE 2004 (+ LOGO
More informationPharmacovigilance information for pharmaceutical companies
Pharmacovigilance information for pharmaceutical companies Electronic transmission of individual case safety reports (ICSRs) with ANSM (French National Agency for the safety of Medicines and Health Products)
More informationGRECO IN THE MIDST OF ITS FOURTH EVALUATION ROUND. Christian Manquet, Vice-President of GRECO
GRECO IN THE MIDST OF ITS FOURTH EVALUATION ROUND Christian Manquet, Vice-President of GRECO GRECO s outreach today: 49 Member States: all Council of Europe member States as well as Belarus and the United
More informationConducting Clinical Trials of Investigational Medicinal Products
Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures
More informationComment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health
Comment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health on the public consultation 1 ASSESSMENT OF THE FUNCTIONING
More informationPhoto: Karpov. Wind in power 2009 European statistics. February 2010 THE EUROPEAN WIND ENERGY ASSOCIATION
Photo: Karpov Wind in power 29 European statistics February 21 1 WIND IN POWER: 29 EUROPEAN STATISTICS Contents Executive summary 29 annual installations Wind map 29 Wind installations 29 Power capacity
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationPublic Consultation on the European Solidarity Corps
Contribution ID: 2d9b4621-cc4d-4c64-a5af-13acac98b4fe Date: 31/03/2017 17:04:55 Public Consultation on the European Solidarity Corps Fields marked with * are mandatory. Introduction The European Solidarity
More informationEthics and Clinical trials EU approach
Ethics and Clinical trials EU approach The view I express are my own and do not necessarily reflect those of the European Commission. NO Yes EU Policy In his main speech after his re-election as President
More informationOver the whole year 2011, GDP increased by 1.4% in the euro area and by 1.5% in the EU27, compared with +1.9% and +2.0% respectively in 2010.
35/2012-6 March 2012 Second estimates for the fourth quarter of Euro area and EU27 down by 0.3% +0.7% and +0.9% respectively compared with the fourth quarter of 2010 decreased by 0.3% in both the euro
More informationGxP Inspections within the Centralised Procedure
GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector 2nd EMEA Workshop for Micro, Small and Medium- Sized Enterprises (SMEs) Focus on Quality Agenda Introduction to work of
More informationLife cycle of a clinical trial. IMB Clinical Trial Seminar June 19 th Dr. Agnieszka Przybyszewska, MD, MSc, PhD, PGDipPharmMed.
Life cycle of a clinical trial IMB Clinical Trial Seminar June 19 th Dr. Agnieszka Przybyszewska, MD, MSc, PhD, PGDipPharmMed. Life cycle of a clinical trial In each MS concerned EUDRA-CT S P O N S O R
More informationEnergy Efficiency Perspectives and Priorities Vleva EUSEW, 24 June 2014
Efficiency Perspectives and Priorities Vleva EUSEW, 24 June 2014 Eva Hoos European Commission Directorate-General for Efficiency Unit 1. Implementation 2. Financing 3. Next steps: 2030 Outline 1. Implementation
More informationClinical Trial Safety Reporting requirements
Clinical Trial Safety Reporting requirements SME info day 20 Mar 2017 Presented by Sophia Mylona Clinical & Non-clinical Compliance, European Medicines Agency An agency of the European Union Article Regulation
More informationEMEA POST-AUTHORISATION GUIDANCE ON PARALLEL DISTRIBUTION
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 19 July 2006 EMEA/Ho/2368/Rev 4 EMEA POST-AUTHORISATION GUIDANCE ON PARALLEL DISTRIBUTION RELEASE FOR CONSULTATION
More informationComposition of the European Parliament
C 227 E/132 Official Journal of the European Union P6_TA(2007)0429 Composition of the European Parliament European Parliament resolution of 11 October 2007 on the composition of Parliament (2007/2169(INI))
More informationGxP Inspections within the Centralised Procedure. Brendan Cuddy Inspections Sector
GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector Agenda Introduction to work of the Inspections Sector GxP Inspections within the centralised procedure Regulatory framework
More informationResource efficiency and waste
Municipal Municipal management across European See also: Country profiles on municipal management 1. Introduction Over the last two decades, European have increasingly shifted their focus with regard to
More informationEU Construction & Demolition Waste Management Protocol Bucharest 17 October 2017
EU Construction & Demolition Waste Management Protocol Bucharest 17 October 2017 European Commission - DG Research & Innovation - Unit I2 Eco-innovation Challenges for Construction and Demolition Waste
More informationII. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD
II. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD Selected Topics Definitions Communication & Interaction Phase I Clinical Trials Safety
More informationVacancy Notice. 1. The job (7)
09.11.2015 1(7) Vacancy Notice The European Chemicals Agency (ECHA) is launching this call for expressions of interest in order to establish a reserve list for the following temporary agent profile: Reference
More informationarena that impact on clinical development
RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European
More informationDeal Making and Product Development in Europe: Changes and Trends You Need to Know About: Regulatory Strategy
Deal Making and Product Development in Europe: Changes and Trends You Need to Know About: Regulatory Strategy Lincoln Tsang Amanda Wearing Jeremy Willcocks November 19, 2004 November 19, 2004 Slide 1 Key
More informationThe European Agency for the Evaluation of Medicinal Products Work Programme 2003
The European Agency for the Evaluation of Medicinal Products Work Programme 2003 Adopted by the Management Board on 19 December 2002 The Work Programme for 2003 is presented by the Executive Director to
More informationEUROPEAN COUNCIL Brussels, 31 May 2013 (OR. en)
EUROPEAN COUNCIL Brussels, 31 May 2013 (OR. en) Interinstitutional File: 2013/0900 (NLE) EUCO 110/13 INST 234 POLG 69 OC 295 LEGAL ACTS Subject: DRAFT EUROPEAN COUNCIL DECISION establishing the composition
More informationRegulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer
Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study Catherine Mathis Director of Regulatory Affairs transgene 1 Disclaimer The views and opinions expressed in the following
More information